Chemical Information | |
Antiviral agent ID | DrugRepV_7991 | |
Antiviral agent name | 3-[2-(4-bromophenyl)-1H-indol-3-yl]-2-[6-({2-[2-(4-bromophenyl)-1H-indol-3-yl]-1-carboxyethyl}carbamoyl)-4-[2-({2-[2-(4-bromophenyl)-1H-indol-3-yl]-1-carboxyethyl}carbamoyl)ethyl]-4-nitrohexanamido]propanoic acid | |
IUPAC Name | 3-[2-(4-bromophenyl)-1H-indol-3-yl]-2-[6-({2-[2-(4-bromophenyl)-1H-indol-3-yl]-1-carboxyethyl}carbamoyl)-4-[2-({2-[2-(4-bromophenyl)-1H-indol-3-yl]-1-carboxyethyl}carbamoyl)ethyl]-4-nitrohexanamido]propanoic acid | |
SMILES (canonical) | OC(=O)C(CC1=C(NC2=C1C=CC=C2)C1=CC=C(Br)C=C1)NC(=O)CCC(CCC(=O)NC(CC1=C(NC2=C1C=CC=C2)C1=CC=C(Br)C=C1)C(O)=O)(CCC(=O)NC(CC1=C(NC2=C1C=CC=C2)C1=CC=C(Br)C=C1)C(O)=O)N(=O)=O | |
Molecular Formula | C61H54Br3N7O11 | |
Molecular Weight (g/mol) | 1300.853 | |
Structural Information | |
|
|
Clinical Information | |
Biological Information | |
Secondary Indication | Human immunodeficiency virus (HIV) 1 NA | |
Secondary Indication (Approaches) | Experimental | |
Secondary Indication (Methods) | In-vitro | |
Secondary Indication (Mode of drug delivery) | Culture
| |
Secondary Indication (Drug concentration) | >30 μM
| |
Secondary Indication (Change) | Decrease
| |
Secondary Indication (Type of Inhibition) | EC50 [ 50 % ] | |
Secondary Indication (Cytotoxicity) | 30 ± 4.3 μM | |
Reference | Martinez-Gualda B, Sun L, Marti-Mari O, Noppen S, Abdelnabi R, Bator CM, Quesada E, Delang L, Mirabelli C, Lee H, Schols D, Neyts J, Hafenstein S, Camarasa MJ, Gago F, San-Felix A..Scaffold Simplification Strategy Leads to a Novel Generation of Dual Human Immunodeficiency Virus and Enterovirus-A71 Entry Inhibitors..J Med Chem. 2020 Jan 9;63(1):349-368. doi: 10.1021/acs.jmedchem.9b01737. PMID:31809045
| |
Comment | Critical for anti-HIV/EV71 activity is the presence of extra phenyl rings, bearing one or two carboxylates, at the C2 position of the indole ring of each Trp residue.
| |